Topic:

R&D

Latest Headlines

Latest Headlines

UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance

In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.

Cebix hangs it up after raising $50M for diabetes drug

La Jolla, CA's Cebix has quietly closed up shop, Xconomy reports, after its once-promising diabetes candidate failed to hit the mark in Phase IIb.

UPDATED: Merck KGaA carves into MS R&D after a string of setbacks

After seeing its reputation as a leader in multiple sclerosis erode over recent years, Merck KGaA has decided to carve back the number of staffers working in preclinical R&D in the field.

Brain cancer therapy pioneered in dogs wins NCI grant for human development

Dogs with spontaneously occurring, highly aggressive brain tumors such as glioblastoma multiforme have proven to be highly accurate models of human brain cancer. So when the owners of a 12-year-old mixed-breed dog with glioblastoma showed up at the Virginia-Maryland Regional College of Veterinary Medicine having exhausted all other treatment options, they agreed to try an experimental technology called nonthermal irreversible electroporation.

UPDATED: Cellectis files for $115M IPO as CAR-T tech sizzles

PARIS-- Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $115 million in the hot American market as it pushes ahead on CAR-T research.

Sanofi's got a new CEO. Now what?

Sanofi has made official what's no longer news, trotting out Olivier Brandicourt as its next chief executive. Stepping in on April 2, the experienced Frenchman inherits a wealth of commercial challenges, a quixotic relationship with local regulators and a make-or-break pipeline the company believes can bring in $38 billion over 5 years.

Cerecor picks up a Lilly antidepressant with ambitions in addiction

Cerecor acquired the rights to an Eli Lilly antidepressant, planning to take the drug into Phase II as a treatment for addictive disorders. 

AstraZeneca picks Labguru to improve collaborations with academia

AstraZeneca has struck a deal with BioData to use Labguru across its preclinical R&D sites. The deal will see AstraZeneca phase out its current patchwork of legacy systems in favor of BioData's web-based lab management system.

Jaguar posts positive trial results on lead prescription drug for dogs

Jaguar Animal Health announced Thursday that during a pilot study of its treatment Canalevia to treat diarrhea, 91% of dogs who received the drug responded positively to it, vs. 50% of dogs who were given a placebo.

Bioartificial adrenal device readies to follow bioartificial pancreas into the clinic

Startup Beta-O2 Technologies already has a bioartificial pancreas in a tiny three-person clinical trial. Now, it has preclinical data for its next device that uses the same implantable bioreactor technology with a new cell type--the βAir Bio-artificial Adrenal system.